Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Increase in Short Interest

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 6,910,000 shares, a growth of 29.2% from the October 31st total of 5,350,000 shares. Based on an average daily trading volume, of 1,460,000 shares, the days-to-cover ratio is presently 4.7 days.

Adaptimmune Therapeutics Price Performance

Shares of ADAP stock traded down $0.00 on Friday, hitting $0.72. 220,906 shares of the stock traded hands, compared to its average volume of 1,720,598. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 52 week low of $0.43 and a 52 week high of $2.05. The firm has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $1.00. The firm has a market cap of $184.41 million, a price-to-earnings ratio of -3.28 and a beta of 2.26.

Analysts Set New Price Targets

A number of analysts have commented on ADAP shares. Mizuho reduced their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating for the company in a report on Wednesday. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research note on Thursday, November 14th. Guggenheim lowered their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. Finally, StockNews.com cut Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $2.79.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC grew its position in shares of Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 21,769 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 30,000 shares during the period. Fullcircle Wealth LLC purchased a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at approximately $33,000. FMR LLC raised its position in shares of Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock valued at $1,655,000 after buying an additional 50,419 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after buying an additional 98,581 shares in the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.